Table 3.
Phase II trials of bevacizumab + chemotherapy in gastric and GEJ tumors
| Regimen | Disease site | n | ORR (%) | Median PFS (months) | Median OS (months) | Reference |
| Cisplatin/irinotecan | GEJ/gastric | 47 | 47 | 8.3 | 12.3 | Shah et al. [20] |
| Docetaxel/cisplatin/5-FU | GEJ/gastric/esophagus | 44 | 67 | 12.0 | 16.2 | Kelsen et al. [21] |
| Docetaxel/cisplatin/irinotecan | GEJ/gastric/esophagus | 26 | 68 | N/A | N/A | Enzinger et al [25] |
| Oxaliplatin/docetaxel | GEJ/gastric | 38 | 42 | 6.6 | 11.1 | Current trial |
GEJ, gastroesophageal junction; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; 5-FU, 5-fluorouracil; N/A, not available.